The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
These findings help explain how relapse-triggering memories can persist alongside those that support recovery
New regional hub strengthens presence in a key market and enhances service delivery for corporate healthcare clients
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
Move comes amid rising regulatory pressures
Pharma giant targets new standards of care
Subscribe To Our Newsletter & Stay Updated
